Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.6 USD | +8.84% | +15.72% | +59.51% |
23/04 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
22/04 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Other languages